London, UK (PRWEB) March 25, 2015
Market Publishers Ltd announces that cutting-edge research reports, worked out by GlobalData, have been recently added to its catalogue.
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is known as a form of cancer that affects the tissues of the colon or rectum. Globally, CRC is one of the most frequently diagnosed form of cancer. Related to the CRC market, colorectal cancer therapeutics market is expected to reach USD 9.4 billion by 2020, showing a 1.8% CAGR. This up-to-date report delves into the exploration of the global CRC market, including the analysis of the market treatment landscape, unmet needs and the current pipeline. Furthermore, the research study offers forecasts along with an overview of the future development trends and potential growth patterns till 2023. Moreover, the publication suggests a comprehensive overview of the currently marketed drugs for CRC and the drugs that will be launched in the market in the years to come.
PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023. Irritable bowel syndrome (IBS) is a disorder in the large intestine that significantly affects the patients’ quality of life (QOL). The disorder is characterized by abdominal discomfort associated with bowel dysfunction. The global IBS market is anticipated to accept new potential therapies till 2023. These new therapies comprise Furiex’s (Actavis’) eluxadoline, Menarini’s ibodutant, Synergy’s plecanatide and AstraZeneca/Ardelyx’s tenapanor. By 2019, the market is expected to increase at a CAGR of 14.04%. The comprehensive research report is aimed at evaluating the situation in the global IBS market, analyzes the development and growth prospects of the market till 2023. It unveils the market data on the key trends, contains a snapshot of innovative products and technologies, and features the market segments. Furthermore, the research study provides an insightful review of the key market drivers, restraints and challenges.
PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023. Macular edema (ME) and macular degeneration (or age-related macular degeneration (AMD)) markets are dominated namely by an anti-VEGF monotherapy, which is likely to be replaced by corticosteroid implants that have recently entered the ME market. The AMD market is anticipated to face the appearance of therapies for the treatment of dry AMD. These therapies are set to satisfy the unfulfilled needs in the treatment of the disease, as well as be a key market growth driver in the years to come. The report describes the present landscape of the ME and AMD markets and also identifies the market future growth prospects and opportunities up to 2023. The study delves into the analysis of the key market vendors and the major challenges faced by the vendors in the market.
PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023. Rheumatoid arthritis (RA) is a chronic autoimmune disorder, which results in inflammation, deformity, pain, stiffness, swelling and limited motion of the joints in hands and feet. Driven by a highly increased number of RA incidences, ageing population in the world and growing expenditure on healthcare worldwide, the RA is considerably competitive for new effective therapies for RA. For instance, the revenues of the world rheumatoid arthritis (RA) drug market are anticipated to be worth USD 38.5 billion in 2017. The in-demand research study provides an elaborate picture of the world RA market. It focuses on the market competitive landscape and dominant players, provides data on the market size, structure and dynamics, and also uncovers extensive forecasts. A review of the current and potential drugs is provided in the research study alongside trustworthy market performance statistical data. The publication includes an analysis of the key RA market trends, threats, opportunities and major drivers.
Other new research reports by the publisher can be found at GlobalData page.